ARCHIVES

SWOG Opens Phase II Trial Of CuraGen’s HDAC Inhibitor For B-Cell Lymphoma

This article is from The Cancer Letter archive.

Vol. 29 No. 9 | September 29, 2006

Download PDF Visit The Full Archive

Related Articles

FDA Approves Taxotere And Gemzar; Sends Approvable Letter For Etopophos

May 24, 1996

NCI Advisors Discuss Cap On Center Core Grants While Broder Complains Cap Is ‘Anti-Intellectual’

May 17, 1991

Industry Groups Lobby for Lower Standards for FDA Approval

November 18, 2011

In Brief: NCI Gets $937 Million For FY 79 As Congress Adjourns; Cancer Act Renewed For Two Years

October 20, 1978

Major Changes In NCI Drug screening Tumor Panels Approved

June 18, 1982

Federal Cigarettes Tax Extension Approved By Senate

October 4, 1985